MedTrace Logo

Effect of Genetic Variation on Efficacy and Safety of Lipid-Lowering Drugs

NCT07008794 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-06-06

No results posted yet for this study

Summary

The primary end point was to reduce LDL-C levels by at least 50%, while the secondary end point was to achieve an LDL-C level below 55 mg/dL. The incidence and specifics of side effects and laboratory abnormalities were recorded throughout the follow-up period to evaluate safeguarding. Liver function tests were performed at baseline and 12 weeks later. Any muscle-related complaints were noted at baseline and during the 12-week sessions. CK total and Hba1c were also assessed

Conditions

  • Acute Coronary Syndromes

Interventions

DRUG

Atorvastatin 40 mg

Rosuvastatin 20 mg

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Hosam Ali Mohamed, Professor · Assiut University

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2022-11-30
Completion
2023-03-31
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07008794 on ClinicalTrials.gov